Tiotropium bromide inhalation - Pulmatrix

Drug Profile

Tiotropium bromide inhalation - Pulmatrix

Alternative Names: PUR-0200; PUR0217a; PUR0228a; PUR0228b; PUR0228c; PUR0230c

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pulmatrix
  • Developer Mylan; Pulmatrix
  • Class Antiasthmatics; Antibronchitics; Epoxy compounds; Esters; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 17 Aug 2017 Chemical structure information added
  • 04 Aug 2017 Pulmatrix plans a pivotal pharmacokinetic bioequivalance study of tiotropium bromide inhalation
  • 09 May 2017 Pulmatrix has patent protection for the tiotropium bromide inhalation product in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top